Akademik Veri Yönetim Sistemi
1st International Symposium on Graduate Research in Science, İstanbul, Türkiye, 4 - 06 Ekim 2018, cilt.26, sa.1, ss.10
Epithelial ovarian cancer (EOC) is the second most important cause of cancer-related
deaths among women worldwide. Due to the mild and common symptoms of EOC, the
disease can not be diagnosed at an early stage. Survival rate in ovarian cancer (OC)
patients is limited to over 80%. When the disease spreads to the upper abdomen or
other parts of the body (stage III and IV), only 20% of the patients survive for 5 years.
Currently, diagnostic methods for EOC are pelvic examination, transvaginal
ultrasonography (TVS) and serum cancer antigen 125 (CA125), however EOC can not
be diagnosed at early stages. CA125 is the only serum biomarker routinely used for
epithelial ovarian cancer and gives 99% certainty, but in postmenopausal women
sensitivity to early disease is only 50-60%[1]. Therefore, finding a reliable biomarker
with increased sensitivity to early stages of epithelial ovarian cancer remains an
important clinical problem.
MicroRNAs (miRNAs) are a class of small non-coding RNAs 18-25 nucleotides in
length. MiRNAs are involved in various biological processes such as cell proliferation,
development, differentiation, apoptosis. MiRNAs display abnormal expression patterns
in different cancer forms. Some act as tumor suppressor genes or oncogenes.
Expression of miRNAs is therefore important in the development of ovarian cancer [2].
Studies have shown that there are differences in miRNA expressions between normal
ovarian epithelial and ovarian cancer epithelial.
Hsa-mir-200c-3p, hsa-mir-4665-3p and hsa-mir-6737-3p expression levels are
upregulated in ovarian cancer tissue to benign cyst samples by microarray results. In
this study, 10 EOC tissue samples and 10 benign cyst samples (BCS) as control were
used and 3 miRNAs expression differences between these 2 groups are validated by
Real-Time PCR method. This project aims to detect biomarkers with transcriptomic
studies in order to extend early 5 years survival time of women with cancer and early
diagnosis of OC.